Australian Industry Hails ‘Landmark’ Shortages Legislation
Bill Described As ‘Watershed Moment In The Security Of Medicine Supply’
Legislation introduced in Australia aimed at mitigating shortages, that enshrines in law provisions of new five-year pharmaceutical industry pacts agreed by the government, has been hailed as a “landmark” development by the GBMA.
You may also be interested in...
A report adopted by the European Parliament calling for measures to support a “greater market presence for generic and biosimilar medicines” has been welcomed by Medicines for Europe.
The WHO and Medicines Patent Pool have announced “the first transparent, global, non-exclusive license for a COVID-19 technology” after striking a deal for a COVID-19 serological antibody technology with the Spanish National Research Council through the WHO’s COVID-19 Technology Access Pool.
After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.